Abstract Recently, we reported an elevated level of glucose-generated carbonyl adducts on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca 2? -ATPase (SERCA2) in hearts of streptozotocin(STZ)-induced diabetic rats. We also showed these adduct impaired RyR2 and SERCA2 activities, and altered evoked Ca 2?
Introduction
World Governments currently spend in excess of $500 billion to diagnose, treat and care for the [350 million individuals with diabetes mellitus (DM) [1, 2] . This syndrome, which is characterized by an elevation in blood glucose, alters the responsiveness of small blood vessels to physiological stimuli, precipitating hypertension and other microvascular-related diseases including stroke, retinopathy, and nephropathy [3] . Approximately, 70 % of individuals with DM will also develop a unique type of heart failure referred to as a diabetic cardiomyopathy, for which the etiology remains poorly understood [4] . What we know to date is that alterations in cellular metabolism, perturbation in sarcoplasmic reticulum (SR) Ca 2? cycling, and stiffening of the extracellular matrix are characteristic features of the diabetic heart [5] [6] [7] [8] . Of interest in our laboratory are the underlying causes for dysregulation in the flow of Ca 2? from and into the SR, an established cause for the reduction in contractility and increased incidence of ventricular arrhythmias in individuals with DM.
The release of Ca 2? from the SR of cardiac ventricular myocytes occurs via type 2 ryanodine receptors (RyR2) and its reuptake into the SR via the sarco(endo)plasmic reticulum Ca 2? -ATPase (SERCA2). Using a rat model of type 1 diabetes, we recently discovered increased carbonylation by the reactive carbonyl species (RCS), methylglyoxal, 3-deoxyglucosone, N e -carboxy(methyl)lysine, and pyrraline is a major cause for RyR2 and SERCA2 dysregulation and the perturbation in myocyte SR Ca 2? cycling [9, 10] . The heart is unique amongst organs in that only 30 % of the ATP needed for functioning is generated from glucose (pyruvate and lactate), with the remaining 70 % of the ATP generated from beta-oxidation of free fatty acids (FFAs) [11, 12] . During DM, expression of the fatty acid transport proteins FATP and CD36 are upregulated and ATP production via oxidation of FFAs is potentiated [12] [13] [14] . More FFAs than that which is required for ATP generation are also taken up, resulting in accumulation of FFAs, triglyceride, phospholipids, and other lipid subspecies inside myocytes [12] . At the same time, ATP production via pyruvate and lactate is downregulated [6, 15] .
In diabetic myocytes, production of reactive oxygen and nitrogen species (ROS/RNS) is also upregulated from increased activation of NADPH oxidase, xanthine oxidases, and nitric oxide synthases, and uncoupling of the mitochondrial electron transport chain [16, 17] . This excess of ROS/RNS react with the FFAs on myocyte membranes, within mitochondria, and in the cytoplasm of myocytes to increase production of the lipid-derived RCS, malondialdehyde (MDA), and 4-hydroxy-2-nonenal (4-HNE) [18] [19] [20] . MDA and 4-HNE production are also upregulated from increased prostaglandin, thromboxane, and arachadonic acid biosynthesis in the diabetic heart [21, 22] . Like glucosederived RCS, MDA and 4-HNE are capable of reacting with nucleophilic groups on proteins (basic and cysteine residues) to form adducts [23, 24] . By acting as a nucleophile, MDA can also react with electrophilic moieties on proteins [24] .
To the best of our knowledge, no data are available to assess if formation of MDA and 4-HNE adducts are also contributing to RyR2 and SERCA2 dysregulation in diabetes. Thus, the objectives of the present study were (i) to determine relative levels of MDA and 4-HNE adducts on RyR2 and SERCA2 from hearts of control and streptozotocin (STZ)-induced diabetic rats with cardiomyopathy and to compare with CML, pentosidine, and pyrraline levels, and (ii) to assess efficacies of tempol (superoxide dismutase mimetic), aminoguanidine (mixed ROS-RCS scavenger), and pyridoxamine (RCS scavenger) treatments to blunt formation of carbonyl adduct formation on RyR2 and SERCA2 and perturbation in myocyte SR Ca 2? cycling.
Materials and methods

Antibodies and reagents
RyR2 and SERCA2 antibodies were obtained from Thermo Fisher Scientific (Waltham, MA). Antibodies to MDA and 4-HNE were obtained from Santa Cruz Biotechnology Inc (Santa Cruz, CA) and EMD Millipore (Billerica, MA) and used at 1:500 and 1:1,000 dilutions. Antibodies to N e -carboxy(methyl)lysine, 3-deoxyglycosone/imidazolone, pentosidine, and pyrraline were provided by Dr. Royji Nagai (Department of Bioscience, Tokai University, Tokyo, Japan) and used at 1:1,000 dilutions. were purchased from GE-Healthcare (Pittsburg, PA). Pyridoxamine, aminoguanidine, and tempol were from SigmaAldrich Chemical (Saint Louis, MO). Fluo-3AM was from Invitrogen (Carlsbad, CA). All other reagents used were of the highest grade commercially available.
Induction and verification of type 1 DM Male Sprague-Dawley rats (200 ± 10 g, Harland Laboratories, Indianapolis, IN) were used in this study and animal procedures used were approved by the Institutional Animal Care and Use Committee, University of Nebraska Medical Center, and adhered to the Guide for the Care and Use of Laboratory Animals [9] . The induction of diabetes with STZ and the care for rats with DM are described in details elsewhere [10, 25] .
Treatment of rats with DM
Two weeks after injection of STZ (45 mg/kg in 0.1 M citrate buffer, pH 4.5), diabetic rats were randomly divided into four groups. The first group was administered tempol (T-D, 0.17 g/L) via drinking water for 5-6 weeks [26, 27] , the second group was given aminoguanidine (Ag-D, 0.14 g/L) [28] , the third group was given pyridoxamine (Py-D, 0.17 g/L) [9] , and the fourth group remained untreated (D). Two weeks after injection with citrate buffer, control animals were also divided into four groups: one group was administered pyridoxamine for 5-6 weeks (Py-C, 0.05 g/L, as they drank one-third less water [29] ), the second group with aminoguanidine (Ag-C, 0.05 g/L), the third group with tempol (TC, 0.05 g/L), and the fourth group remained untreated (C). Water bottles containing tempol, aminoguanidine, and pyridoxamine were wrapped around with aluminum foil to protect them from light and changed daily.
Establishing diabetic cardiomyopathy in vivo
M-mode echocardiography M-mode echocardiography was performed at the end of the 8-week protocol in anaesthetized animals (100 mg/kg ketamine/2.5 mg/kg acepromazine, i.p.) to establish reduced left ventricular fraction shortening and ejection fraction [25] . Rats were lightly anesthetized with ketamine-acepromazine and left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular enddiastolic volume (LVEDV), and left ventricular end-systolic volume (LVESV) were assessed using a Vevo 770 TM High Resolution In Vivo Micro Imaging System (Visual Sonics Inc, Toronto, Canada). Percent fractional shortening (FS) was calculated using the equation FS = [(LVEDD -LVESD)/ LVEDD] 9 100. Percent ejection fraction (EF) was calculated using the equation EF = [(LVEDV -LVESV)/ LVEDV] 9 100.
In vivo hemodynamics
Basal and isoproterenol-induced changes in rates of left ventricular pressure rise and decline (-dP/dt), peak left ventricular pressure (LVP), and LVEDV were evaluated as described earlier [30] . Briefly, animals were anesthetized with Inactin (thiobutabarbital, sodium salt, 20 mg/kg given i.p.) and their left carotid arteries were isolated and cannulated with Millar catheters containing a pressure transducer. Each Millar catheter was fed into the artery until it reaches inside the left ventricle for assessment of pressure changes during contraction/relaxation cycle. Right hind leg femoral vein was also cannulated and used for injection of isoproterenol. A Powerlab, a computer-based data acquisition system (ADInstruments) was used for obtaining basal heart rate, left ventricular pressure, ±dP/dT, and arterial blood pressure.
Blood parameters
Blood samples were collected via left renal arteries after deep anesthesia and assayed for glucose, insulin, thiobarbituric acid-reactive substances (predominantly MDA), % glycosylated hemoglobin, and semicarbazidesensitive amine oxidase as described previously [10, 28] .
Assessment of evoked Ca
2? transients Ventricular myocytes were isolated through retrograde collagenase perfusion and evoked Ca 2? transients were assessed as described previously [25, 28] 
Assessment of myocyte contractile kinetics
Contraction kinetics of myocytes were assessed using highspeed video-based edge detection system (IonOptix Corporation, Milton, MA) described previously [30] . For this, myocytes in DMEM were placed in a Warner chamber mounted on the stage of an inverted microscope (Zeiss X-40, Thornwood, NJ) at room temperature (22-24°C). Cells were then field stimulated at 0.5 Hz (10 V for 10 ms) using a pair of platinum wires placed on opposite sides of the chamber and movements were recorded using a proprietary data acquisition program (IonOptix Corporation, Milton, MA). Rates of myocyte shortening and relengthening and extent of cell shortening were then calculated using IonWizard version 5.0.
RyR2 activity
The ability of RyR2 to bind the Ca 2? -dependent binding [ 3 H]ryanodine was used as an index of its activity. For this, crude SR membranes (0.1 mg/ml) prepared as described earlier [9] were incubated in binding buffer (500 mM KCl, 20 mM Tris-HCl, 0.3 mM Ca 2? , 2 mM reduced glutathione, and 100 lM EGTA, 6.7 nM [ 3 H]ryanodine, pH 7.4) for 2 h at 37°C. After incubation, membranes were filtered and washed, and the amount of [ 3 H]ryanodine bound was determined using liquid scintillation counting. Non-specific binding was determined simultaneously by incubating vesicles with 1 lM unlabeled ryanodine [30] .
SERCA2 activity
The ability of SERCA2 to transport Ca 2? (steps 1 through 6 of the Post-Elbers cycle) was used as an index of its activity. Crude SR membrane vesicles were resuspended in 1 ml buffer (30 mM Tris-HCl, pH 7.0, 100 mM KCl, 5 mM NaN 3 , 50 lM ryanodine, 5 mM MgCl 2 , 0.15 mM EGTA, 0.12 mM CaCl 2 , 1 lCi 45 Ca 2? , and 10 mM potassium oxalate) and were divided into 2 9 500 ll aliquots. One aliquot was incubated with a SERCA2a inhibitor cocktail (10 lM thapsigargin, 100 lM ammonium molybdate, 0.05 lg bafilomycin) and the other aliquot remained untreated. Ca 2? uptake was initiated by the addition of ATP (Na 2 ATP) and after 20 min SR vesicles were cold-filtered and washed as described earlier [10] . The amount of 45 Ca 2? remaining on the filter paper was used as a measure of SERCA2 activity.
Determination of carbonyl adducts
Ventricular homogenates (60 lg) and crude SR membranes (30 lg) prepared from hearts of control, diabetic and were solubilized in gel dissociation medium and electrophoresed on Criterion 4-15 % gradient Tris-glycine polyacrylamide gels (BioRad Technologies Inc, Burlingame, CA) for 210 min at 150 V. For experiments involving lipid-derived adducts, Criterion TGX gels were used (BioRad Inc, Burlingame CA). At the end the electrophoresis, proteins were transferred onto polyvinylidene difluoride membranes (PVDF, Millipore Corporation, Bedford, MA, 100 mA, 16 h at 4°C) using a semi-dry electroblotter (Panther; Owl Scientific Inc., Woburn, MA) with CAPS buffer (10 mM cyclohexylamino-1-propanesulfonic acid/0.01 % SDS in 10 % methanol, pH 9.0) and western blots were performed with adduct-specific antibodies to determine MDA, 4-HNE, N e -carboxy(methyl)lysine, pentosidine, and pyrraline adducts. Primary antibodies against MDA and 4-HNE adducts were used at 1:1,000 and 1:500 dilutions, antibodies against N e -carboxy(methyl)lysine, pentosidine, and pyrraline adducts were used at 1:1,000 dilutions, and secondary antibodies were used at 1:5,000 dilutions. All gels were stained with Coommasie Blue dye after semi-dry transfer to assess sample loading [9, 10] .
Determination of protein identity
After semi-dry transfer, gels were stained with Coomassie Blue dye and destained with 25 % methanol. Protein bands corresponding to those with carbonyl adduct (RyR2, SERCA2, NCX, myosin heavy chain, MHC) were excised, digested with trypsin, desalted with ZipTips Ò (Millipore, Billerica, MA) and subjected to matrix-assisted laser desorption ionization time-of-flight and Tandem mass spectrometry as described earlier [9, 10] . Peptide sequences were submitted to Mascot Wizard Search Engine to confirm identity (Matrix Science, Boston, MA).
Statistical analysis
Differences among RyR2 and SERCA2 values from each of the groups (C, D, Py-C, Py-D, Ag-C, Ag-D, T-C, and T-D) were evaluated using analysis of variance (ANOVA) employing GraphPad Prism. Data are presented as mean ± SEM. The results were considered significantly different if p \ 0.05 (95 % confidence interval). Table 1 shows the general characteristics of animals employed in this study. Diabetes increased % glycosylated hemoglobin, serum thiobarbituric acid-reactive substances (TBARS), and semicarbazide-sensitive amine oxidase (SSAO) activity. Pyridoxamine (Py), aminoguanidine (Ag), or tempol (T) treatments did not significantly differently alter body weight, blood glucose, % glycosylated hemoglobin, or serum insulin. However, pyridoxamine treatment significantly lowered SSAO activity (p \ 0.05) while aminoguanidine and tempol treatments lowered serum TBARS (p \ 0.05).
Results
Establishing diabetic cardiomyopathy
M-Mode echocardiography
After 7-8 weeks of diabetes, EF, % FS and heart rate were significantly (p \ 0.05) reduced in diabetic rats compared with controls, indicative of a cardiomyopathy ( Fig. 1(i) ; Table 2 , left lanes).
In vivo hemodynamics
Basal and isoproterenol-induced heart rates, rates of left ventricular pressure increase and decline (-dP/dt) and peak left ventricular pressure (LVP) were also significantly (p \ 0.05) lower in diabetic rats compared to controls ( Fig. 1(ii) , (iii); Table 2 , left lanes), consistent with diabetic cardiomyopathy. Left ventricular end-diastolic pressure (LVEDP) was significantly (p \ 0.05) elevated in diabetic rats compared to controls.
Evoked Ca 2? transient kinetics
After Ca 2? reconstitution, 68 ± 6 % of myocytes from control rats were rod-shaped and viable, 53 ± 5 % were rod-shaped and viable from diabetic rats, 65 ± 6 % were rod-shaped and viable from pyridoxamine-treated diabetic rats, 63 ± 6 % were rod-shaped and viable from aminoguanidine-treated diabetic rats, and 56 ± 2 % were rodshaped and viable from tempol-treated diabetic rats. (Fig. 1(v) ; Table 3 , right lanes), consistent with altered SR Ca 2? cycling. About 35 % of diabetic myocytes also exhibited diastolic Ca 2? release in between stimulation.
Confirming reduced RyR2 and SERCA2 activities
RyR2
Steady state levels of RyR2 protein did not change after 7-8 weeks of diabetes ( Fig. 1(vi) , upper autoradiogram) [9, 30] . At equivalent amounts of protein, RyR2 from diabetic rat hearts bound significantly (p \ 0.05) less [ 3 H]ryanodine than RyR2 from control hearts, consistent with a net reduction in activity ( Fig. 1(vi) , graph).
SERCA2
Steady state SERCA2, monomeric, and pentameric PLN proteins also remained unchanged after 7-8 weeks of diabetes ( Fig. 1(vii) ) [10] . However, SERCA2 from diabetic rat was less effective in transporting Ca 2? .
Carbonyl adducts on RyR2 and SERCA2
MDA and 4-HNE adducts were not detected on RyR2 or SERCA2 proteins from hearts of control and diabetic rats using 30 lg of SR membranes and 1:1,000 dilution of primary antibodies (Figs. 2, left lanes, 3, left lanes). Higher amounts of SR membrane proteins (75 lg) and increased concentration of antibodies (1:500) also did not revealed MDA and 4-HNE adduct on RyR2 and SERCA2 (data not shown). MDA adducts were detected on other proteins in the SR preparations (M w * 13 kDa, *40 kDa, *45 kDa, *56 kDA, *70 kDa, *85 kDa, and *200 kDa, Fig. 2 , left lanes, indicating that the antibodies were detecting immuno-reactive MDA adducts. With an exception of the protein band at *50 kDa, the amount of MDA adducts did not change with DM. 4-HNE adducts were also detected on proteins of M w * 4 kDa, *10 kDa, *44 kDa, *48 kDa, and *66 kDa (Fig. 3) , indicating that the antibodies were detecting immuno-reactive 4-HNE adducts.
In agreement with recent reports [9, 10] , in this study elevated levels of immuno-reactive N e -carboxy(methyl)lysine, pentosidine, and pyrraline adducts were formed on RyR2 and Table 1 General characteristics of animals used in the study
Tempol-treated
Body mass (g) 393.0 ± 13. . Values shown are mean ± SEM for four separate experiments SERCA2 in diabetes (Figs. 4, 5, 6 , left lanes, p \ 0.05). Higher levels of pentosidine (80 %), and pyrraline (250 %) adducts were also found on the sodium-calcium exchanger (NCX) from diabetic rat (Figs. 4, 5) . N e -carboxy(methyl) lysine and pentosidine adducts were also significantly (p \ 0.05) elevated (two-to threefold) on several yet to be identified proteins in diabetic rat hearts (Figs. 3, 4 , black arrows). Comparison between aminoguanidine, pyridoxamine, and tempol treatments
M-mode echocardiography
Treating diabetic rats with pyridoxamine and aminoguanidine for 6 weeks, starting 2 weeks after the onset of DM significantly (p \ 0.05) increased EF and percent FS (Table 4) . Tempol treatment did not attenuate the loss in cardiac EF and percent FS (Table 4) . Pyridoxamine, aminoguanidine and tempol treatments did not blunted the slowing in heart rate.
In vivo hemodynamics
Treating diabetic rats with pyridoxamine, aminoguanidine, or tempol for 6 weeks, starting 2 weeks after the onset of DM significantly (p \ 0.05) blunted the reduction in rate of LVP development (?dP/dt) and enhanced the responsiveness of diabetic hearts to isoproterenol stimulation (Table 4) . Pyridoxamine and aminoguanidine also (p \ 0.05) increased basal peak LVP and rate of LVP decline (-dP/dt) and lowered left ventricular end-diastolic pressure (LVEDP) ( Table 4) .
Myocyte contractile kinetics
Treating diabetic rats with pyridoxamine, aminoguanidine, or tempol for 6 weeks, starting 2 weeks after the onset of DM significantly (p \ 0.05) blunted the reduction in myocyte contraction velocity induced by DM (Table 5) . Only pyridoxamine and aminoguanidine blunted the reduction in extent in cell shortening. Pyridoxamine, aminoguanidine, and tempol treatments also significantly (p \ 0.05) enhanced myocyte relaxation rate (Table 5) .
Evoked Ca 2? transient kinetics
Pyridoxamine and aminoguanidine treatments significantly (p \ 0.05) enhanced the rate of evoked Ca 2? rise in ventricular myocytes from diabetic rats, but not tempol treatment ( Fig. 7 ; Table 5 ). Although there were substantial increases in the Ca 2? transient amplitudes in myocytes from pyridoxamine-treated, aminoguanidinetreated, and tempol-treated diabetic myocytes, these increases did not attain statistical significance (p = 0.07). Pyridoxamine, aminoguanidine, and tempol shortened evoked Ca 2? transient decay time (Table 5 ) and reduced diastolic Ca 2? release in between pulses (Fig. 7) .
Carbonyl adducts on RyR2 and SERCA2
MDA and 4-HNE adducts were not detected on RyR2 and SERCA2 proteins from pyridoxamine-, aminoguanidine-, and tempol-treated diabetic rat hearts (Figs. 2, 3 ). Tempol treatment, did lower the amount of MDA adduct on a protein of M w * 50 kDa (Fig. 2 ) and a protein with 4-HNE adduct with M w * 42 kDa (Fig. 3) . Treating diabetic animals with either pyridoxamine or aminoguanidine blunted the increase in N e -carboxy(methyl)lysine, pentosidine, and pyrraline on RyR2 and SERCA2, but not on all SR proteins (Figs. 4, 5, 6 , 
RyR2 and SERCA2 activities
Pyridoxamine, aminoguanidine, and tempol treatments did not alter expressions of RyR2 (Fig. 8) and SERCA2 (Fig. 9) . Interestingly, only pyridoxamine and aminoguanidine treatments significantly (p \ 0.05) blunted the loss in RyR2 activity (as assessed using [ 3 H]ryanodine binding to RyR2, and ability of SERCA2 to transport Ca 2? induced by DM (Figs. 8, graph below, 9 , graph below).
Discussion
Individuals with chronic and/or long-standing DM have reduced cardiac contractile function and are more likely to develop stress-induced arrhythmias, compared with agematched individual [31] . These defects are attributed in part to perturbation in the flow of Ca 2? out of and into the SR arising from dysregulation of RyR2 and SERCA2, respectively [32] [33] [34] [35] . However, the molecular mechanisms underlying RyR2 and SERCA2 dysregulation during release. Data are mean ± SEM; n = 60 cells or more cells from 6 to 7 hearts. *p \ 0.05 for diabetic treated compared to diabetic untreated hearts diabetes remains incompletely defined. We recently showed that these slowly turned over Ca 2? cycling proteins (t 1/2 * 8 days for RyR2, and t 1/2 * 14 days for SERCA2, [35] ) become post-translationally modified by glucosederived RCS during DM, and that formation of these adducts are responsible in part for their dysregulation. We also showed that oxidation of cysteine residues also contributes to RyR2 dysregulation during DM, but the identity of these cysteine residues remains undefined [36] . What is not clear is if lipid-derived RCS like MDA and 4-HNE also post-translationally modify and alter the function of RyR2 and SERCA2 in DM.
The principal finding of the present study is that RyR2 and SERC2A from hearts of control animals and STZinduced diabetic rats with established diabetic cardiomyopathy do not contain either MDA or 4-HNE adducts. This conclusion is based on extensive western blotting assays using ventricular homogenates and SR membranes enriched in RyR2 and SERCA2, and several highly selective commercially available antibodies that immuno-reacts specifically with MDA adducts (N e -b-lysyl-aminoacrolein and N d -(2-pyrimidyl)-L-orinithine) and 4-HNE adducts. MDA and 4-HNE antibodies were used at two times the recommended manufactures' dilutions (1:500) and with up to 75 lg SR membrane proteins/lane in SDS-PAGE gels. Although RyR2 and SERCA2 were not chemically modified by MDA and 4-HNE, several proteins in our SR membrane preparations were, indicating that these antibodies were detecting immuno-reactive MDA and 4-HNE adducts. These data are consistent with studies reported by Shah et al. [37] and Minamiyama et al. [38] . Why some proteins in our preparations (control) are post-translationally modified by MDA and 4-HNE while others are not, remains undefined. What we suspect is that our SR preparations contain proteins from other intracellular organelles including mitochondria, Golgi, cytoplasm, and cell membranes that reside in proximity to where MDA and 4-HNE are synthesized.
Although MDA is upregulated in DM, its ability to rearrange at neutral and physiological pHs to the less reactive enol form [23] could account for the absence of adducts on RyR2 and SERCA2. Another reason could be the reduction in expression of the MDA degrading enzyme, aldehyde dehydrogenase (ADLH2) [39] . Conversion of cytoplasmic MDA to methylglyoxal [40] and degradation of methylglyoxal to D-lactate by glyoxalase I and II and reduced glutathione [41] may also contribute. In diabetes, increased expression and activity of aldose reductase, the major enzyme that degrades 4-HNE, may also help explain the reduction in 4-HNE adducts on proteins [42] . Increased expression of glutathione S-transferases (GSTA4-4 and GST5.8) may also contribute [43] .
In this study, glucose-generated N e -carboxy(methyl) lysine, pentosidine, and pyrraline adducts were significantly (p \ 0.05) elevated on RyR2, SERCA2, and NCX isolated from diabetic rat hearts (Figs. 4, 5, 6 ). What was . Data shown are mean ± SEM for four separate experiments; *Significantly different from control (p \ 0.05). **Significantly different from diabetic (p \ 0.05) also apparent from the autoradiograms was that N e -carboxy(methyl)lysine, pentosidine, and pyrraline adducts were more likely to be formed on proteins M w [ 200 kDa and \30 kDa (Figs. 4, 5, 6 ), while MDA and 4-HNE adducts were more likely to be formed on proteins of M w between 30 and 80 kDa (Figs. 2, 3) . The reason(s) for the selectivity in proteins targeted for MDA and 4-HNE, and by N e -carboxy(methyl)lysine, pentosidine, and pyrraline remains incompletely understood.
Another major finding of the present study is that treating diabetic rats with tempol was less effective than treatment with aminoguanidine and pyridoxamine in blunting cardiac function loss. Pyridoxamine and aminoguanidine treatments increased percent cardiac FS, EF, peak ± dP/dt, basal LVP, and reduced LVEDP, while tempol treatment restored ?dP/dt. Pyridoxamine and aminoguanidine treatments also significantly improved myocyte contraction and relaxations rates, extent of cell shortening and rates of Ca 2? release and uptake from the SR. Hearts from pyridoxamine-and aminoguanidine-animals were also more responsive to isoproterenol-induced contraction/relaxation compared with hearts from tempoltreated animals (Table 4) . These data are not in agreement with those of Shi et al. [44] , who found that oral administration of tempol (2 mmol/L) for 6 weeks after coronary artery ligation prevented the signs of cardiac dysfunction and failure manifest as an increase in left ventricular enddiastolic pressure and volume, reduced EF and enhanced renal sympathetic nerve activity and plasma norepinephrine. The reason(s) for the discrepancy in our data is not clear at this time. One reason could be differences in the models. The second may be the amount of tempol administered may be toxic. Diabetic rats typically drink[3 times more water than control rats (300 ± 40 mL compared with 80 ± 10 mL per day for controls), resulting in nearly 1.2 lmol/kg/day tempol being consumed [45] . Since tempol reduces ROS production/generation through its superoxide dismutase mimetic action, scavenges O 2 Á-, exhibits catalase-like action, and reduces NADPH-dependent O 2 Á-generation [27] , we expected tempol treatment to reduce ventricular stiffening and increase cardiac distensibility by reducing activation of metalloproteinases [27, 46, 47] , In this study, tempol treatment also did not improve RyR2 or SERCA2 activities, suggesting that ROS/ superoxide is unlikely to be the primary cause for their dysregulation in diabetes.
The third major finding of the present study is that pyridoxamine is more efficacious than aminoguanidine in reducing formation of glucose-generated N e -carboxy(methyl) lysine, pentosidine, and pyrraline adducts on RyR2 and SERCA2 in diabetic rats. This conclusion is in agreement with earlier studies by Voziyan and Hudson [48] who indicated that pyridoxamine, but not aminoguanidine, strongly inhibited the formation of N e -carboxy(methyl)lysine by directly scavenging RCS. At this time, it is not clear if the higher hydrophilic properties of aminoguanidine prevent it from entering the cell and attenuating carbonylation of RyR2 and SERCA2 [49] . From its chemical structure, pyridoxamine is less hydrophilic and therefore more likely to enter cells and scavenge RCS. In addition to its ability to scavenge RCS, aminoguanidine also inhibits nitric oxide synthases and semicarbazide-sensitive amine oxidase [49] which may dilute its RCS scavenging actions in vivo. Pyridoxamine also alters ROS production, but this effect is secondary to its RCS scavenging actions.
In conclusion, this study shows for the first time that lipidderived MDA and 4-HNE adducts are not formed on RyR2 or SERCA2 in either control or diabetic rat hearts. The reason for this unexpected finding is not clear at this time. What we do know is that MDA rearrange at physiological pH to form the less reactive enol derivative, and expression of enzymes that degrades it, aldehyde dehydrogenase is downregulated in the heart in diabetes expression and activity of aldose reductase, the enzyme that metabolizes 4-HNE is also upregulated in the heart during diabetes. In a recent study Sansbury et al. [50] indicated that hypertrophied myocytes had an increased propensity to oxidize 4-HNE and sustained less protein damage when challenged acutely with 4-HNE. In this study treating diabetic animals with the RCS scavengers, pyridoxamine and aminoguanidine were more efficacious in blunting the development of a diabetic cardiomyopathy than treatment with the ROS/superoxide scavenger, tempol, and that this beneficial effect is due in part to reducing formation of glucose-generated RCS adducts on the principal intracellular Ca 2? cycling proteins RyR2 and SERCA2.
